View on Pubmed.gov 27486774 | View on doi.org 10.18632/oncota...
Ubc13: the Lys63 ubiquitin chain building machine.
- Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada.
Abstract
Ubc13 is an ubiquitin E2 conjugating enzyme that participates with many different E3 ligases to form lysine 63-linked (Lys63) ubiquitin chains that are critical to signaling in inflammatory and DNA damage response pathways. Recent studies have suggested Ubc13 as a potential therapeutic target for intervention in various human diseases including several different cancers, alleviation of anti-cancer drug resistance, chronic inflammation, and viral infections. Understanding a potential therapeutic target from different angles is important to assess its usefulness and potential pitfalls. Here we present a global review of Ubc13 from its structure, function, and cellular activities, to its natural and chemical inhibition. The aim of this article is to review the literature that directly implicates Ubc13 in a biological function, and to integrate structural and mechanistic insights into the larger role of this critical E2 enzyme. We discuss observations of multiple Ubc13 structures that suggest a novel mechanism for activation of Ubc13 that involves conformational change of the active site loop.
References
Mol Cell. 2008 Mar 14;29(5):625-36
J Biol Chem. 2016 Apr 29;291(18):9396-410
Biochem Cell Biol. 2007 Aug;85(4):509-20
Dev Biol. 2013 Aug 15;380(2):211-21
Cited by 74 citations (total)
Journal Article Research Support, Non-U.S. Gov't
Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461.
Electronic publication date October 21, 2021
Tehmina Masud [...] Samuel Aparicio et al.
CX-5461 is a G-quadruplex (G4) ligand currently in trials with initial indications of clinical activity in cancers with defects in...
Journal Article Review
An Update on Development of Small-Molecule Plasmodial Kinase Inhibitors.
Electronic publication date April 22, 2021
Chantalle Moolman [...] Lesetja J Legoabe et al.
Malaria control relies heavily on the small number of existing antimalarial drugs. However, recurring antimalarial drug resistance necessitates the continual...
Conflict of interest statement
MeSH
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •